Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Jun J. Mao(Memorial Sloan Kettering Cancer Center), Angela DeMichele(University of Pennsylvania), H. Irene Su(University of California San Diego), Richard Aplenc(Children's Hospital of Philadelphia), Frank Z. Stanczyk(University of Southern California), Rui Feng(University of Pennsylvania), Timothy R. Rebbeck(University of Pennsylvania), Michelle Donelson(University of Pennsylvania)
Breast Cancer Research
January 20, 2011
10.1186/bcr2813
Cited by 99

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Assessment of cumulative evidence on genetic associations: interim guidelines
|International Journal of Epidemiology|2007|549
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|507